# Genzyme Corporation - Inspection Records

Source: https://www.keypedia.com/companies/genzyme-corporation/b597b205-d758-426b-bc64-09970b3a1b83

> Inspection records and compliance data for Genzyme Corporation in Framingham, Massachusetts. Access full analysis and detailed observations.

---

## Details

- Name: Genzyme Corporation
- FEI Number: 1220423
- City: Framingham
- State: Massachusetts
- Country Name: United States
- Address Line 1: 8, 31,45,49,51,55,68,74,76,80 New York Ave.
- Zip Code: 01701

## Related Documents

- [FDA Inspection 1294652 - Genzyme Corporation - 2026-04-09](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/6cbe5f5c-7096-43eb-a766-5583af3a17c8) — source: FDA, date: April 9, 2026
- [483 - Genzyme Corporation - 2024-07-09](https://www.keypedia.com/records/483/genzyme-corporation/5b6ddbd8-75e1-4493-89cc-36eb3e3200af) — source: FDA, date: July 9, 2024
- [WARNING_LETTER - Genzyme Corporation - 2024-07-09](https://www.keypedia.com/records/warning_letter/genzyme-corporation/8a3ec574-4474-4308-b227-407524c4d420) — source: FDA, date: July 9, 2024
- [FDA Inspection 1232210 - Genzyme Corporation - 2024-07-09](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/a68d998d-31e2-47dc-b3c9-bfb31e8d55f1) — classification: Official Action Indicated (OAI), source: FDA, date: July 9, 2024
- [483 - Genzyme Corporation - 2022-07-25](https://www.keypedia.com/records/483/genzyme-corporation/23883a1e-c563-4d35-85ce-e1cb99b21cb1) — source: FDA, date: July 25, 2022
- [483 - Genzyme Corporation - 2022-07-25](https://www.keypedia.com/records/483/genzyme-corporation/349b695a-f390-44c5-b321-aa0f01ee5183) — source: FDA, date: July 25, 2022
- [FDA Inspection 1176107 - Genzyme Corporation - 2022-07-25](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/302d437c-4efe-4525-98e6-0ab1a2ff5e82) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 25, 2022
- [EIR - Genzyme Corporation - 2022-06-25](https://www.keypedia.com/records/eir/genzyme-corporation/6eb86bff-8103-449e-b583-0fb676d5acb3) — source: FDA, date: June 25, 2022
- [483 - Genzyme Corporation - 2020-09-04](https://www.keypedia.com/records/483/genzyme-corporation/894c0fc4-69ad-498f-9313-26d2ae12d839) — source: FDA, date: September 4, 2020
- [EIR - Genzyme Corporation - 2020-09-04](https://www.keypedia.com/records/eir/genzyme-corporation/9e7a9f46-31eb-4d3b-9af7-a9f9dea767de) — source: FDA, date: September 4, 2020
- [483 - Genzyme Corporation - 2020-09-04](https://www.keypedia.com/records/483/genzyme-corporation/92fb5a72-64b2-4547-a360-5fbd53dbb20b) — source: FDA, date: September 4, 2020
- [FDA Inspection 1003362 - Genzyme Corporation - 2017-02-02](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/6b833ff5-3c9a-4425-89ea-dcf002ab8a8a) — classification: No Action Indicated (NAI), source: FDA, date: February 2, 2017
- [FDA Inspection 904958 - Genzyme Corporation - 2014-11-21](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/6ac675e6-81a7-438c-9541-db54fdf5ac25) — classification: Voluntary Action Indicated (VAI), source: FDA, date: November 21, 2014
- [FDA Inspection 897241 - Genzyme Corporation - 2014-09-25](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/53b1a390-ea9d-45a9-a773-3d85e1671b56) — classification: Voluntary Action Indicated (VAI), source: FDA, date: September 25, 2014
- [FDA Inspection 791919 - Genzyme Corporation - 2012-07-13](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/03b4ccc4-639a-46dd-b816-32fccd5fd7f3) — classification: Voluntary Action Indicated (VAI), source: FDA, date: July 13, 2012
- [FDA Inspection 684675 - Genzyme Corporation - 2010-10-22](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/81df17e8-9782-4308-9965-3fc0c82e6140) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 22, 2010
- [FDA Inspection 554509 - Genzyme Corporation - 2008-12-05](https://www.keypedia.com/records/fda_inspections/genzyme-corporation/e6beac0a-ea40-4ed1-9abe-2a5970e5c13b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: December 5, 2008

## Related Companies

- [Hovione LLC](https://www.keypedia.com/companies/hovione-llc/06b4417a-5377-4e73-8076-71d3066fa8f0)
- [Wacker Biotech B.V.](https://www.keypedia.com/companies/wacker-biotech-bv/9bd47c05-6585-4710-a9ea-4bd04e15dd4f)
- [Symbiosis Pharmaceutical Services Limited](https://www.keypedia.com/companies/symbiosis-pharmaceutical-services-limited/ec055812-aec1-48cd-a034-44081f00bf5f)
- [Alexion Pharma International Operations Unlimited Co.](https://www.keypedia.com/companies/alexion-pharma-international-operations-unlimited-co/7c523c79-b4b1-4a47-8393-141753fd60e8)
- [Avista Pharma Solutions, Inc. dba Cambrex](https://www.keypedia.com/companies/avista-pharma-solutions-inc-dba-cambrex/ca9e4205-cd7f-44bd-8dbe-a9d98be57047)
- [Brammer Bio MA, LLC](https://www.keypedia.com/companies/brammer-bio-ma-llc/df01a45e-77d0-4179-bd95-978ebd2395a6)
- [AGC Biologics SPA](https://www.keypedia.com/companies/agc-biologics-spa/aca43856-193e-492b-9512-0f72b2680e90)
- [Boehringer Ingelheim Biopharmaceuticals (China) Ltd.](https://www.keypedia.com/companies/boehringer-ingelheim-biopharmaceuticals-china-ltd/be450a8b-4f71-4f06-96b3-908a2ed1b580)
- [ANTHEM BIOSCIENCES PRIVATE LIMITED - Phase II](https://www.keypedia.com/companies/anthem-biosciences-private-limited-phase-ii/df5d2c40-b402-492b-9369-42c7f15f0a08)
- [VGXI, Inc.](https://www.keypedia.com/companies/vgxi-inc/74b43bde-de6a-4ab6-825e-e8f3598e221f)

## Related Officers

- [issuing_officer](https://www.keypedia.com/people/ying-xin-fan/905eacc9-1394-4215-9fbc-61c151c0debe)
- [Senior Regulatory Specialist](https://www.keypedia.com/people/wayne-e-seifert/e92e1f10-c61e-4b08-9156-25907e5e2942)